$50.04
arrow_drop_down1.43%Key Stats | |
---|---|
Open | $50.39 |
Prev. Close | $50.77 |
EPS | -5.79 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 48.45 | 52.00 |
52 Week Range | 3.03 | 61.90 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -5.79 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'